David A Gorelick Selected Research

Substance-Related Disorders (Drug Abuse)

1/2019	N-Acetylcysteine in Treatment of Substance Use Disorders.
7/2015	Morphine and codeine in oral fluid after controlled poppy seed administration.
10/2014	Transcranial magnetic stimulation in the treatment of substance addiction.
10/2013	Smoking and opioid detoxification: behavioral changes and response to treatment.
6/2012	State of the art treatments for cannabis dependence.
12/2011	Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population.
10/2011	MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.
8/2011	Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration.
2/2011	Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
7/2009	The future of endocannabinoid-oriented clinical research after CB1 antagonists.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Gorelick Research Topics

Disease

15	Substance-Related Disorders (Drug Abuse) 01/2019 - 01/2002
7	Schizophrenia (Dementia Praecox) 08/2023 - 02/2011
7	Cocaine-Related Disorders (Cocaine Addiction) 10/2010 - 01/2002
6	Marijuana Abuse (Cannabis Abuse) 02/2018 - 01/2011
5	Opioid-Related Disorders (Opiate Addiction) 01/2014 - 01/2004
3	Psychotic Disorders (Schizoaffective Disorder) 01/2016 - 02/2011
3	Substance Withdrawal Syndrome (Withdrawal Symptoms) 05/2014 - 10/2011
2	Alcoholism (Alcohol Abuse) 10/2022 - 11/2018
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 02/2018 - 01/2016
2	Weight Loss (Weight Reduction) 11/2014 - 02/2011
2	Overweight 02/2013 - 02/2011
2	Obesity 02/2011 - 07/2009
2	Cardiac Arrhythmias (Arrythmia) 09/2009 - 01/2008
2	Wounds and Injuries (Trauma) 01/2007 - 01/2007
1	Treatment-Resistant Schizophrenia 08/2023
1	Neutropenia 08/2023
1	Binge Drinking 10/2022
1	Pain (Aches) 01/2022
1	Mental Disorders (Mental Disorder) 11/2018
1	Fatigue 03/2016
1	Neoplasms (Cancer) 11/2014
1	Sleepiness 09/2013
1	Anxiety Disorders (Anxiety Disorder) 12/2011
1	Weight Gain 02/2011
1	Hyperlipidemias (Hyperlipidemia) 02/2011
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2009
1	Tachycardia (Tachyarrhythmias) 11/2007
1	Dizziness (Lightheadedness) 03/2006
1	Hypotension (Low Blood Pressure) 03/2006
1	Delirium 07/2004
1	Tobacco Use Disorder (Nicotine Dependence) 04/2003

Drug/Important Bio-Agent (IBA)

8	Cocaine (Cocaine HCl)IBA 03/2016 - 01/2004
7	RimonabantIBA 02/2013 - 03/2006
6	Dronabinol (THC)FDA LinkGeneric 01/2016 - 03/2006
4	Antipsychotic Agents (Antipsychotics)IBA 08/2023 - 07/2004
4	Opioid Analgesics (Opioids)IBA 01/2022 - 11/2008
3	CannabinoidsIBA 11/2018 - 07/2009
3	Nicotine FDA Link 02/2018 - 01/2002
3	Hypnotics and Sedatives (Sedatives)IBA 05/2014 - 07/2004
3	Opiate AlkaloidsIBA 01/2014 - 01/2004
3	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 10/2011 - 01/2008
2	Serotonin (5 Hydroxytryptamine)IBA 10/2022 - 01/2007
2	SmokeIBA 11/2018 - 06/2012
2	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 02/2018 - 01/2016
2	Clonidine (ST 155)FDA LinkGeneric 10/2013 - 05/2012
2	Bromocriptine (Parlodel)FDA LinkGeneric 02/2006 - 01/2002
2	Buprenorphine (Subutex)FDA LinkGeneric 04/2005 - 01/2004
1	Clozapine (Clozaril)FDA LinkGeneric 08/2023
1	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 10/2022
1	Serotonin AgentsIBA 10/2022
1	Ondansetron (Zofran)FDA LinkGeneric 10/2022
1	Biomarkers (Surrogate Marker)IBA 10/2022
1	Ethanol (Ethyl Alcohol)IBA 10/2022
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 10/2022
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2019
1	Propranolol (Inderal)FDA LinkGeneric 01/2016
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2016
1	rasagiline (Azilect)FDA Link 07/2015
1	Morphine (MS Contin)FDA LinkGeneric 07/2015
1	Analgesics (Analgesic Drugs)IBA 11/2014
1	Methadone (Dolophine)FDA LinkGeneric 05/2012
1	Heroin (Diamorphine)IBA 12/2011
1	EndocannabinoidsIBA 02/2011
1	Buspirone (Buspar)FDA LinkGeneric 01/2011
1	atrolactic acid (HMMA)IBA 03/2009
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2007
1	Illicit Drugs (Recreational Drugs)IBA 01/2007
1	Hallucinogens (Psychedelics)IBA 01/2007
1	Naloxone Drug Combination Buprenorphine FDA Link 10/2006
1	Dopamine Agonists (Dopamine Agonist)IBA 02/2006
1	ProlactinIBA 02/2006
1	ButyrylcholinesteraseIBA 07/2005
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2004
1	Dopamine (Intropin)FDA LinkGeneric 01/2004
1	SolutionsIBA 01/2004
1	A-factor (Streptomyces)IBA 04/2003
1	Bupropion (Wellbutrin)FDA LinkGeneric 01/2002

Therapy/Procedure

2	Self Medication 01/2022 - 12/2011
2	Drug Therapy (Chemotherapy) 02/2018 - 02/2011
1	Pain Management 03/2016
1	Transcranial Magnetic Stimulation 10/2014
1	Length of Stay 01/2006